^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | Hormone Receptor Positive Breast Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) + ipatasertib (RG7440) (PI3K inhibitor, AKT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase Ib/II open-label, randomized trial of atezolizumab (atezo) with ipatasertib (ipat) and fulvestrant (fulv) vs control in MORPHEUS-HR+ breast cancer (M-HR+ BC) and atezo with ipat vs control in MORPHEUS triple negative breast cancer (M-TNBC)
Published date:
10/09/2021
Excerpt:
In M-HR+ BC, none of whom received prior fulvestrant, 26 pts received atezo + ipat + fulv....Confirmed ORRs were 23.1% (95% CI: 9.0, 43.7) and 0% (95% CI: 0, 21.8), respectively. Median PFS was 4.4 mo (95% CI: 1.6, not evaluable) and 1.9 mo (95% CI: 1.6, 3.9), respectively....Atezo + ipat + fulv was tolerable with a preliminary efficacy signal in HR+ BC.
Secondary therapy:
fulvestrant
Trial ID:
